Cancer as a robust system: implications for anticancer therapy

A genetic model for colorectal tumorigenesis

Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · see citing works

Stem cells, cancer, and cancer stem cells

Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · see citing works

Error and attack tolerance of complex networks

Albert, R., Jeong, H., & Barabási, A.-L. (2000) · Nature · doi:10.1038/35019019 · Cited by 7,534 · see citing works

Targeting HIF-1 for cancer therapy

Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Error and attack tolerance of complex networksPreprint

Albert, R., Jeong, H., & Barabási, A.-Ĺ. (2000) · Cited by 6,554 · see citing works

Involvement of chemokine receptors in breast cancer metastasis

Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340 · see citing works

Hypoxia — a key regulatory factor in tumour growth

Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · see citing works

The Large-Scale Organization of Metabolic Networks

Jeong, H., Tombor, B., Albert, R., Oltvai, Z. N., & Barabási, A.-L. (2000) · Nature · doi:10.1038/35036627 · Cited by 4,972 · see citing works

Systems biology: a brief overview

Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265 · see citing works

Genetic instabilities in human cancers

Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168 · cited 1× · see citing works

Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase

Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · see citing works

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

Juliano, R. L., & Ling, V. W. T. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,317 · see citing works

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · see citing works

Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects

Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662 · see citing works

The microenvironment of the tumour–host interface

Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,322 · see citing works

Computational systems biology.

Kitano, H. (2002) · Nature · doi:10.1038/nature01254 · Cited by 2,209 · see citing works

Putting tumours in context

Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180 · see citing works

Negative Control of p53 by Sir2α Promotes Cell Survival under Stress

Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081 · see citing works

Stochastic mechanisms in gene expression.

McAdams, H., & Arkin, A. (1997) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.94.3.814 · Cited by 1,970 · see citing works

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,870 · see citing works

Addiction to Oncogenes--the Achilles Heal of Cancer

Weinstein, I. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,753 · see citing works

Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix.

Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schäffer, U., & Vaupel, P. W. (1996) · PubMed · Cited by 1,727 · see citing works

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · see citing works

Robustness in simple biochemical networks

Barkai, N., & Leibler, S. (1997) · Nature · doi:10.1038/43199 · Cited by 1,513 · see citing works

Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459 · see citing works

DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance

DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333 · see citing works

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311 · see citing works

The complexity of p53 modulation: emerging patterns from divergent signalsPreprint

Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,303 · see citing works

Reverse engineering of biological complexity

Csete, M. E., & Doyle, J. C. (2002) · Science · doi:10.1126/science.1069981 · Cited by 1,215 · see citing works

Angiostatin induces and sustains dormancy of human primary tumors in mice

O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170 · see citing works

The segment polarity network is a robust developmental module

von Dassow, G., Meir, E., Munro, E. M., & Odell, G. M. (2000) · Nature · doi:10.1038/35018085 · Cited by 1,144 · see citing works

Robustness in bacterial chemotaxis

Alon, U. S., Surette, M. G., Barkai, N., & Leibler, S. (1999) · Nature · doi:10.1038/16483 · Cited by 1,129 · see citing works

Robust perfect adaptation in bacterial chemotaxis through integral feedback control

Yi, T., Huang, Y. H., Simon, M. I., & Doyle, J. C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4649 · Cited by 1,038 · see citing works

Multidrug resistance (MDR) in cancer

Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,032 · see citing works

Control, exploitation and tolerance of intracellular noise

Rao, C. V., Wolf, D. M., & Arkin, A. P. (2002) · Nature · doi:10.1038/nature01258 · Cited by 1,006 · see citing works

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., & Nakamura, Y. (2000) · Nature · doi:10.1038/35003506 · Cited by 904 · see citing works

Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL

Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870 · see citing works

It’s a noisy business! Genetic regulation at the nanomolar scale

McAdams, H. H., & Arkin, A. P. (1999) · Trends in Genetics · doi:10.1016/s0168-9525(98)01659-x · Cited by 848 · see citing works

Complexity and robustness

Carlson, J. M., & Doyle, J. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012582499 · Cited by 815 · see citing works

Multiple mutations and cancer

Loeb, L. A., Loeb, K. R., & Anderson, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0334858100 · Cited by 762 · see citing works

Genetic instability and darwinian selection in tumours

Cahill, D. P., Kinzler, K. W., Vogelstein, B., & Christoph Lengauer, C. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01661-x · Cited by 747 · see citing works

Engineered gene circuits

Hasty, J., McMillen, D. R., & Collins, J. J. (2002) · Nature · doi:10.1038/nature01257 · Cited by 744 · see citing works

Sir2 links chromatin silencing, metabolism, and agingPreprint

Guarente, L. (2000) · Genes & Development · doi:10.1101/gad.14.9.1021 · Cited by 718 · see citing works

Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC

Jain, M., Arvanitis, C., Chu, K., Dewey, W. C., Leonhardt, E. A., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 647 · see citing works

Mechanisms of Tumor Progression

Conti, C. J. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.01417-2 · Cited by 607 · see citing works

Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study

Bar‐Or, R. L., Maya, R. B.-Y., Segel, L. A., Alon, U., Levine, A. J., & Oren, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210171597 · Cited by 579 · see citing works

Viral quasispecies.

Eigen, M. (1993) · Scientific American · doi:10.1038/scientificamerican0793-42 · Cited by 576 · see citing works

Calorie Restriction, Aging, and Cancer Prevention: Mechanisms of Action and Applicability to Humans

Hursting, S. D., Lavigne, J. A., Berrigan, D. A., Perkins, S. N., & Barrett, J. C. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152156 · Cited by 558 · see citing works

Highly optimized tolerance: A mechanism for power laws in designed systems

Carlson, J. M., & Doyle, J. C. (1999) · Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics · doi:10.1103/physreve.60.1412 · Cited by 555 · see citing works

Introducing SOSTOOLS: a general purpose sum of squares programming solver

Prajna, S., Papachristodoulou, A., & Parrilo, P. A. (2003) · Proceedings of the IEEE Conference on Decision & Control, including the Symposium on Adaptive Processes · doi:10.1109/cdc.2002.1184594 · Cited by 554 · see citing works

Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling

Ghiso, J. A. A., Kovalski, K., & Ossowski, L. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.147.1.89 · Cited by 546 · see citing works

Circadian clocks limited by noise

Barkai, N., & Leibler, S. (2000) · Nature · doi:10.1038/35002258 · Cited by 536 · see citing works

'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally

García‐Cao, I., García‐Cao, M., Martín‐Caballero, J., Criado, L. M., Klatt, P., Flores, J. M., Weill, J., Blasco, M. A., & Serrano, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf595 · Cited by 529 · see citing works

The genetic origin of drug resistance in neoplasms: implications for systemic therapy.

Goldie, J. H., & Coldman, A. J. (1984) · PubMed · Cited by 518 · see citing works

ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK)

Aguirre‐Ghiso, J. A., Estrada, Y. D., Liu, D., & Ossowski, L. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2003.12.012 · Cited by 465 · see citing works

How does calorie restriction work?Preprint

Koubova, J., & Guarente, L. (2003) · Genes & Development · doi:10.1101/gad.1052903 · Cited by 457 · see citing works

Urokinase Receptor and Fibronectin Regulate the ERKMAPK to p38MAPK Activity Ratios That Determine Carcinoma Cell Proliferation or Dormancy In Vivo

Aguirre‐Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K., & Ossowski, L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.4.863 · Cited by 447 · see citing works

Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 437 · see citing works

Computational Cell Biology

Fall, C. P., Marland, E., Wagner, J., et al. (2004) · Springer eBooks · doi:10.1007/b97701 · Cited by 409 · see citing works

Chemokines: agents for the immunotherapy of cancer?

Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398 · see citing works

Biological consequences of tumor hypoxia

ckel, M. H., & Vaupel, P. W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90211-8 · Cited by 381 · see citing works

Tumor hypoxia: A target for selective cancer therapy

Kizaka‐Kondoh, S., Inoue, M., Harada, H., & Hiraoka, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01395.x · Cited by 353 · see citing works

ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).

Aguirre‐Ghiso, J. A., Estrada, Y. D., Liu, D., & Ossowski, L. (2003) · PubMed · Cited by 350 · see citing works

Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.

Naumov, G. N., MacDonald, I. C., Weinmeister, P. M., Kerkvliet, N. I., Nadkarni, K. V., Wilson, S. M., Morris, V. L., Groom, A. C., & Chambers, A. F. (2002) · PubMed · Cited by 341 · see citing works

Error catastrophe and antiviral strategy

Eigen, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212514799 · Cited by 339 · see citing works

Tumor reversion: Correction of malignant behavior by microenvironmental cues

Kenny, P. A., & Bissell, M. J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11491 · Cited by 328 · see citing works

The p53 functional circuit

Jin, S. V., & Levine, A. J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.23.4139 · Cited by 310 · see citing works

Robustness of a gene regulatory circuit

Little, J. W., Shepley, D. P., & Wert, D. W. (1999) · The EMBO Journal · doi:10.1093/emboj/18.15.4299 · Cited by 275 · see citing works

SIMULATION OF PROKARYOTIC GENETIC CIRCUITS

McAdams, H. H., & Arkin, A. P. (1998) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.27.1.199 · Cited by 274 · see citing works

Roots of Clinical Resistance to STI-571 Cancer Therapy

Barthe, C., Cony‐Makhoul, P., Melo, J. V., & Reiffers, J. J. (2001) · Science · doi:10.1126/science.293.5538.2163a · Cited by 271 · see citing works

Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis

Weinstein, I. B. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.857 · Cited by 266 · see citing works

Aneuploidy vs. gene mutation hypothesis of cancer: Recent study claims mutation but is found to support aneuploidy

Li, R., Sonik, A., Stindl, R., Rasnick, D., & DUESBERG, P. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3236 · Cited by 258 · see citing works

Cancer chronotherapy: Principles, applications, and perspectives

Mormont, M., & Lévi, F. (2002) · Cancer · doi:10.1002/cncr.11040 · Cited by 251 · see citing works

Cancer immunotherapy: The past, the present and the future

Parish, C. R. (2003) · Immunology and Cell Biology · doi:10.1046/j.0818-9641.2003.01151.x · Cited by 240 · see citing works

Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression.

Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R., & Giaccia, A. J. (1996) · PubMed · Cited by 239 · see citing works

Aneuploidy, the somatic mutation that makes cancer a species of its own

DUESBERG, P. H., & Rasnick, D. (2000) · Cell Motility and the Cytoskeleton · doi:10.1002/1097-0169(200010)47:2 · Cited by 229 · see citing works

Robustness as a Measure of Plausibility in Models of Biochemical Networks

Morohashi, M., WINN, A. E., Borisuk, M. T., Bolouri, H., Doyle, J. C., & Kitano, H. (2002) · Journal of Theoretical Biology · doi:10.1006/jtbi.2002.2537 · Cited by 226 · see citing works

Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells

Damert, A., Ikeda, E., & Risau, W. (1997) · Biochemical Journal · doi:10.1042/bj3270419 · Cited by 216 · see citing works

Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein

Levy, A. P., Levy, N. S., & Goldberg, M. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25492 · Cited by 213 · see citing works

Linking chromatin function with metabolic networks: Sir2 family of NAD+-dependent deacetylases

Denu, J. M. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)00005-1 · Cited by 208 · see citing works

Multidrug resistance (mdr) genes in human cancer

Nooter, K., & Herweijer, H. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.152 · Cited by 206 · see citing works

Metapopulation dynamics and spatial heterogeneity in cancer

González-Garcı́a, I., Solé, R. V., & Costa, J. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202139299 · Cited by 201 · see citing works

Robustness, Flexibility, and the Role of Lateral Inhibition in the Neurogenic Network

Meir, E., von Dassow, G., Munro, E., & Odell, G. M. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00839-4 · Cited by 193 · see citing works

Cancer dormancy: Opportunities for new therapeutic approaches

Uhr, J. W., Scheuermann, R. H., Street, N. E., & Vitetta, E. S. (1997) · Nature Medicine · doi:10.1038/nm0597-505 · Cited by 188 · see citing works

Tumors are unique organs defined by abnormal signaling and context

Radisky, D. C., Hagios, C., & Bissell, M. J. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0360 · Cited by 177 · see citing works

Analysis of switched and hybrid systems - beyond piecewise quadratic methods

Prajna, S., & Papachristodoulou, A. (2004) · Proceedings of the ... American Control Conference/Proceedings of the American Control Conference · doi:10.1109/acc.2003.1243743 · Cited by 166 · see citing works

Robust Oscillations within the Interlocked Feedback Model of Drosophila Circadian Rhythm

Ueda, H. R., Hagiwara, M., & Kitano, H. (2001) · Journal of Theoretical Biology · doi:10.1006/jtbi.2000.2226 · Cited by 166 · see citing works

Exploiting cancer cell cycling for selective protection of normal cells.

Blagosklonny, M. V., & Pardee, A. B. (2001) · PubMed · Cited by 157 · see citing works

Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity.

Fujii, H., Yoshida, M., Gong, Z. X., et al. (2000) · PubMed · Cited by 152 · see citing works

Dynamic Heterogeneity: Rapid Generation of Metastatic Variants in Mouse B16 Melanoma Cells

Hill, R. P., Chambers, A. F., Ling, V. W. T., & Harris, J. F. (1984) · Science · doi:10.1126/science.6719130 · Cited by 152 · see citing works

Toward a chronotherapy of neoplasia: Tolerance of treatment depends upon host rhythms

Franz Halberg, A., Haus, E. L., Cardoso, S., Scheving, L. E., Jf, K., Shiotsuka, R. N., Rosene, G. L., Pauly, J. E., RUNGE, W. J., Spalding, J. F., et al. (1973) · Cellular and Molecular Life Sciences · doi:10.1007/bf01930381 · Cited by 152 · see citing works

Tumor progression: a brief historical perspective

Nowell̀, P. C. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00012-3 · Cited by 150 · see citing works

Cancer robustness: Tumour tactics

Kitano, H. (2003) · Nature · doi:10.1038/426125a · Cited by 146 · see citing works

Human Sir2 and the ‘silencing’ of p53 activity

Smith, J. S. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)02342-5 · Cited by 141 · see citing works

Bifurcation Analysis of a Model of Mitotic Control in Frog Eggs

Borisuk, M. T., & Tyson, J. J. (1998) · Journal of Theoretical Biology · doi:10.1006/jtbi.1998.0781 · Cited by 139 · see citing works

Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor.

Harris, J. F., Chambers, A. F., Hill, R. P., & Ling, V. W. T. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.18.5547 · Cited by 137 · see citing works

Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma

Baisse, B., Bouzourène, H., Saraga, E. P., Bosman, F. T., & Benhattar, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1343 · Cited by 137 · see citing works

The tumor metabolome.

Mazurek, S., & EIGENBRODT, E. (2003) · PubMed · Cited by 136 · see citing works

A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis.

Guba, M., Cernaianu, G., Koehl, G. E., et al. (2001) · PubMed · Cited by 121 · see citing works

Cytogenetic analysis of pancreatic carcinomas: Intratumor heterogeneity and nonrandom pattern of chromosome aberrations

Gorunova, L., Höglund, M., Andrén‐Sandberg, Å., Dawiskiba, S., Jin, Y., Mitelman, F., & Johansson, B. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199810)23:2 · Cited by 117 · see citing works

MDM2 Oncogene as a Novel Target for Human Cancer Therapy

Zhang, R., & Wang, H. (2000) · Current Pharmaceutical Design · doi:10.2174/1381612003400911 · Cited by 111 · see citing works

Solitary cancer cells as a possible source of tumour dormancy?

Naumov, G. N., MacDonald, I. C., Chambers, A. F., et al. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0382 · Cited by 110 · see citing works

A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity

Haigis, K. M., & Dove, W. F. (2002) · Nature Genetics · doi:10.1038/ng1055 · Cited by 88 · see citing works

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance

Verweij, J., Herweijer, H., Oosterom, R., der Burg, M. V., Planting, A. S. T., Seynaeve, C., Stoter, G., & Nooter, K. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.307 · Cited by 71 · see citing works

Hypoxia‐induced pathways in breast cancer

Goonewardene, T. I., Sowter, H., & Harris, A. L. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10175 · Cited by 70 · see citing works

Computational cell biology

Mellman, I., & Misteli, T. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200303202 · Cited by 66 · see citing works

T-cell immunity in the induction and maintenance of a tumour dormant state

Schirrmacher, V. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0384 · Cited by 66 · see citing works

Promises and pitfalls of anti-angiogenic therapy in clinical trials

McCarty, M. F., Liu, W., Fan, F., Parikh, A. A., Reimuth, N., Stoeltzing, O., & Ellis, L. M. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00002-9 · Cited by 65 · see citing works

Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect.

He, S., & Fm, S. (1984) · PubMed · Cited by 64 · see citing works

Cytogenetic and molecular mechanisms of resistance to imatinib

Hochhaus, A. (2003) · Seminars in Hematology · doi:10.1053/shem.2003.50045 · Cited by 62 · see citing works

Modulation of P-Glycoprotein (PGP) Mediated Multidrug Resistance (MDR) Using Chemosensitizers: Recent Advances in the Design of Selective MDR Modulators

Krishna, R., & Mayer, L. D. (2001) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011013354705 · Cited by 60 · see citing works

Phase transitions in unstable cancer cell populations

Solé, R. V. (2003) · The European Physical Journal B · doi:10.1140/epjb/e2003-00262-8 · Cited by 57 · see citing works

Clinical pharmacokinetics of anti-metabolites.

Peters, G. J., Schornagel, J. H., & Milano, G. A. (1993) · PubMed · Cited by 55 · see citing works

Tumour dormancy: not so sleepy after all

Murray, C. (1995) · Nature Medicine · doi:10.1038/nm0295-117 · Cited by 54 · see citing works

Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.

Sb, K. (1998) · PubMed · Cited by 52 · see citing works

Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer

Rodenburg, C. J., Nooter, K., Herweijer, H., et al. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057941 · Cited by 52 · see citing works

Dynamic heterogeneity and metastasis

Ling, V. W. T., Chambers, A. F., Harris, J. F., et al. (1984) · Journal of Cellular Physiology · doi:10.1002/jcp.1041210412 · Cited by 43 · see citing works

The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics

Zheleva, D. I., Lane, D. P., & Fischer, P. M. (2003) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557033488178 · Cited by 42 · see citing works

Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy

Rasnick, D. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00665-3 · Cited by 39 · see citing works

Antiangiogenesis: Current Clinical Data and Future Perspectives

Drevs, J., Laus, C., Medinger, M., et al. (2002) · Oncology Research and Treatment · doi:10.1159/000068622 · Cited by 36 · see citing works

Immediate Local and Regional Recurrence After the Excision of a Polypoid Melanoma: Tumor Dormancy or Tumor Activation?

GIORGI, V. D., Massi, D., Gerlini, G., et al. (2003) · Dermatologic Surgery · doi:10.1046/j.1524-4725.2003.29163.x · Cited by 30 · see citing works

T Cell Memory, Anergy and Immunotherapy in Breast Cancer

Schirrmacher, V., Feuerer, M., Beckhove, P., Ahlert, T., & Umansky, V. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1020308104613 · Cited by 27 · see citing works

Power law distribution of chromosome aberrations in cancer.

Frigyesi, A., Gisselsson, D., Mitelman, F., et al. (2003) · PubMed · Cited by 25 · see citing works

Somatic recombination redux

Tischfield, J. A., & Shao, C. (2002) · Nature Genetics · doi:10.1038/ng0103-5 · Cited by 23 · see citing works

Extensive cytogenetic heterogeneity in a benign retroperitoneal schwannoma

Gorunova, L., Dawiskiba, S., Andrén‐Sandberg, Å., Höglund, M., & Johansson, B. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00440-4 · Cited by 15 · see citing works

Dynamic heterogeneity: characterization of two cell lines derived from experimental lung metastases of mouse KHT fibrosarcoma.

Jf, H., Chambers, A. F., Ling, et al. (1987) · PubMed · Cited by 13 · see citing works

[Chronobiology and cancer].

Lévi, F. A. (1987) · PubMed · Cited by 6 · see citing works

Lack of Effectiveness of Adjuvant Alternating Chemotherapy in Node-Positive, Estrogen-Receptor-Negative Premenopausal Breast Cancer Patients: Results of a Multicentric Italian Study

Boccardo, F., RUBAGOTTI, A., AMOROSO, D., et al. (1997) · Cancer Investigation · doi:10.3109/07357909709047591 · Cited by 4 · see citing works

Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85)

and cooperating investigators, Chacon, R., Acuña, L. R., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.423 · Cited by 2 · see citing works

Biological robustness

Kitano, H. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1471 · Cited by 2,278 · see citing works

Robustness of cellular functions

Stelling, J., Sauer, U., Szallasi, Z., Doyle, F. J., & Doyle, J. (2004) · Cell · doi:10.1016/j.cell.2004.09.008 · Cited by 1,049 · see citing works

A robustness-based approach to systems-oriented drug design

Kitano, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2195 · Cited by 488 · see citing works

Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities

Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415 · see citing works

Cell fate decision mediated by p53 pulses

Zhang, X.-P., Liu, F., Cheng, Z., & Wang, W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813088106 · Cited by 253 · see citing works

Novel aspects of oxidative stress-associated carcinogenesis

Toyokuni, S. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1373 · Cited by 104 · see citing works

Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine

Dalla Pozza, E., Fiorini, C., Dando, I., Menegazzi, M., Sgarbossa, A., Costanzo, C., Palmieri, M., & Donadelli, M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.06.007 · Cited by 84 · see citing works

Barium nanoparticles enhance efficacy of external beam radiation therapy in a preclinical basal-like mammary cancer mouse model

Albers, J., Markus, A., Svetlove, A., Kraupner, A., Briel, A., Alves, F., & Dullin, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-02560-4 · Cited by 3 · see citing works

Radioimmunonanoparticles for Cancer Imaging and Therapy

Natarajan, A. (2011) · doi:10.1002/9780470767047.ch31 · Cited by 1 · see citing works

Recent Advances of Diketopyrrolopyrrole Derivatives in Cancer Therapy and Imaging Applications

Wang, L., Lai, B., Ran, X., Tang, H., & Cao, D. (2023) · Molecules · doi:10.3390/molecules28104097 · Cited by 22 · see citing works

Advances in targeting strategies for nanoparticles in cancer imaging and therapy

Yhee, J. Y., Lee, S., & Kim, K. (2014) · Nanoscale · doi:10.1039/c4nr04334k · Cited by 61 · see citing works

Nanoparticles for Combined Cancer Imaging and Therapy

Bagalkot, V., Yu, M. K., & Jon, S. (2011) · doi:10.1002/9780470767047.ch23 · Cited by 2 · see citing works

New Generation of Multifunctional Nanoparticles for Cancer Imaging and Therapy

Park, K., Lee, S., Kang, E., Kim, K., Choi, K., & Kwon, I. C. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200801655 · Cited by 430 · see citing works